Silke Retlich

Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase‐4 inhibitor linagliptin ^*

Ulrike Graefe‐Mody, Christian Friedrich, Andreas Port et al. · Diabetes Obesity and Metabolism · 2011 · 185 citations

Pharmacokinetics of linagliptin in subjects with hepatic impairment

Ulrike Graefe‐Mody, Peter W. Rose, Silke Retlich et al. · British Journal of Clinical Pharmacology · 2012 · 76 citations · Full text

Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses (0.5 mg–10 mg) and Determination of Absolute Bioavailability of the Dipeptidyl Peptidase-4 Inhibitor Linagliptin (BI 1356) in Healthy Male Subjects

Silke Retlich, Vincent Duval, Arne Ring et al. · Clinical Pharmacokinetics · 2010 · 48 citations

Molecular Pharmacology, Therapeutic Drug Monitoring, Pharmacokinetic Modeling +11

Binding to dipeptidyl peptidase‐4 determines the disposition of linagliptin (BI 1356) – investigations in DPP‐4 deficient and wildtype rats

Silke Retlich, B. Withopf, Andreas Greischel et al. · Biopharmaceutics & Drug Disposition · 2009 · 46 citations

Molecular Pharmacology, Neuropeptides, Signal Transduction +14

Impact of Target‐Mediated Drug Disposition on Linagliptin Pharmacokinetics and DPP‐4 Inhibition in Type 2 Diabetic Patients

Silke Retlich, Vincent Duval, Ulrike Graefe‐Mody et al. · The Journal of Clinical Pharmacology · 2010 · 46 citations

Diabetes Management, Inhibitor Linagliptin, Pharmacokinetic Modeling +15